卡那单抗对后续痛风发作及高敏C反应蛋白水平的影响:因果中介分析
本研究对卡那单抗抗炎血栓形成结局研究(CANTOS)中的痛风发作进行事后因果中介分析,以3个月时对数高敏C反应蛋白(hsCRP)水平变化为中介变量。在无 prevalent 痛风患者中,卡那单抗与安慰剂相比痛风发作的HR为0.50(95%CI 0.37-0.68),其中6%由hsCRP降低中介;在 prevalent 痛风亚组中HR为0.58(95%CI 0.36-0.95),31%由hsCRP降低中介。结论认为整体队列中3个月hsCRP降低并非卡那单抗保护作用的好生物标志物,但在 prevalent 痛风患者中可能具有潜在作用。
要点
- 整体队列中卡那单抗 vs 安慰剂痛风发作HR 0.50(95%CI 0.37-0.68),仅6%由hsCRP降低中介。
- prevalent 痛风亚组HR 0.58(95%CI 0.36-0.95),31%由hsCRP降低中介,Weibull分析中介比例为47%。
- 无 prevalent 痛风亚组中经hsCRP降低的间接效应不明确。
核心结论
- 整体队列中,最初3个月hsCRP水平降低并非卡那单抗对未来痛风发作保护作用的良好生物标志物。
- 在 prevalent 痛风患者中,早期hsCRP水平降低可能作为白介素-1β抑制剂未来痛风发作获益的生物标志物具有潜在作用。
研究设计与样本
- 对卡那单抗抗炎血栓形成结局研究(CANTOS)中痛风发作进行的事后因果中介分析。
- 以3个月时对数hsCRP水平变化为中介变量,采用线性回归处理hsCRP中介,Cox或Weibull回归处理痛风发作结局,并整合于因果中介分析。
- 分析总体队列并按基线时是否存在 prevalent 痛风进行分层。
- 分析纳入无 prevalent 痛风患者9,221例和 prevalent 痛风患者747例。
主要发现
- 在无 prevalent 痛风患者中,卡那单抗 vs 安慰剂痛风发作的Cox回归HR为0.50(95%CI 0.37-0.68),其中6%由最初3个月hsCRP水平降低的中介效应解释。
- 在 prevalent 痛风亚组中,卡那单抗 vs 安慰剂痛风发作的HR为0.58(95%CI 0.36-0.95),其中31%由hsCRP水平降低的中介效应解释。
- Weibull分析给出的中介比例估计为47%。
- 在无 prevalent 痛风亚组中,经hsCRP水平降低的间接效应不明确。
关键数值与推荐
- 无 prevalent 痛风患者:卡那单抗 vs 安慰剂痛风发作HR 0.50(95%CI 0.37-0.68),中介比例6%。
- prevalent 痛风患者:卡那单抗 vs 安慰剂痛风发作HR 0.58(95%CI 0.36-0.95),中介比例31%。
- Weibull分析中介比例估计为47%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to quantify the value of early suppression of high-sensitivity C-reactive protein (hsCRP) levels as a biomarker of the protective role of canakinumab against future gout flares. METHODS: We conducted a post hoc causal mediation analysis of the Canakinumab Anti-Inflammatory Thrombosis Outcome Study for gout flares. The 3-month change in the log hsCRP level was the mediator of interest. We used linear regression for the hsCRP level mediator and Cox or Weibull regression for gout-flare outcomes, combining them in causal mediation analysis. We examined the cohort overall, as well as stratified by prevalent gout at baseline. RESULTS: We analyzed 9,221 patients without prevalent gout and 747 with prevalent gout. The Cox regression hazard ratio (HR) for a gout flare was 0.50 (95% confidence interval [95% CI] 0.37-0.68) comparing canakinumab with placebo, of which 6% was explained by the mediated effect through hsCRP level reduction in the first 3 months. In the prevalent-gout subgroup, the HR was 0.58 (95% CI 0.36-0.95), of which 31% was explained by the mediated effect through hsCRP level reduction. The Weibull analysis gave a proportion-mediated estimate of 47%. The indirect effect via hsCRP level reductions was unclear in the subgroup without prevalent gout. CONCLUSION: The first 3-month reduction in hsCRP level was not a good biomarker for canakinumab's protective effect on future gout flares in the overall cohort. Among patients with prevalent gout, there may be a potential role for early hsCRP level reduction as a biomarker for interleukin-1β inhibitors' future gout-flare benefit.
引用
- Yoshida K, Glynn RJ, Choi HK, et al. Canakinumab's Effect Against Subsequent Gout Flares and High-Sensitivity C-Reactive Protein Levels: A Causal Mediation Analysis. Arthritis Care Res (Hoboken). 2022. PMID: 34874116. doi:10.1002/acr.24832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。